697761-98-1 | 6-(3-Chloro-2-fluorobenzyl)-1-[1(S)-(hydroxymethyl)-2-methylpropyl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid

Packsize	Purity	Availability	Price	Discounted Price
1mg	95%	in stock	$26.00	$18.00
5mg	95%	in stock	$52.00	$36.00
10mg	95%	in stock	$65.00	$45.00
50mg	95%	in stock	$117.00	$82.00
100mg	95%	in stock	$178.00	$124.00
250mg	95%	in stock	$352.00	$246.00
1g	95%	in stock	$879.00	$615.00

Description

• Catalog Number: AB73366
• Chemical Name: 6-(3-Chloro-2-fluorobenzyl)-1-[1(S)-(hydroxymethyl)-2-methylpropyl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
• CAS Number: 697761-98-1
• Molecular Formula: C23H23ClFNO5
• Molecular Weight: 447.8838
• MDL Number: MFCD11846134
• SMILES: OC[C@@H](n1cc(C(=O)O)c(=O)c2c1cc(OC)c(c2)Cc1cccc(c1F)Cl)C(C)C

Computed Properties

• Complexity: 702
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 1
• Heavy Atom Count: 31
• Hydrogen Bond Acceptor Count: 7
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 7
• XLogP3: 5.3

Literature

• Characterization and in vitro activity of a branched peptide boronic acid that interacts with HIV-1 RRE RNA.

  Bioorganic & medicinal chemistry 20160901

• Antiviral characteristics of GSK1265744, an HIV integrase inhibitor dosed orally or by long-acting injection.

  Antimicrobial agents and chemotherapy 20150101

• Basic quinolinonyl diketo acid derivatives as inhibitors of HIV integrase and their activity against RNase H function of reverse transcriptase.

  Journal of medicinal chemistry 20140424

• Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness.

  Antimicrobial agents and chemotherapy 20130601

• A novel anti-HIV active integrase inhibitor with a favorable in vitro cytochrome P450 and uridine 5'-diphospho-glucuronosyltransferase metabolism profile.

  Antiviral research 20130601

• Carbamoyl pyridone HIV-1 integrase inhibitors. 2. Bi- and tricyclic derivatives result in superior antiviral and pharmacokinetic profiles.

  Journal of medicinal chemistry 20130214

• Ruthenium arene complexes as HIV-1 integrase strand transfer inhibitors.

  Journal of inorganic biochemistry 20130101

• The hepatitis B virus ribonuclease H is sensitive to inhibitors of the human immunodeficiency virus ribonuclease H and integrase enzymes.

  PLoS pathogens 20130101

• Dual inhibition of HIV-1 replication by integrase-LEDGF allosteric inhibitors is predominant at the post-integration stage.

  Retrovirology 20130101

• Carbamoyl pyridone HIV-1 integrase inhibitors. 1. Molecular design and establishment of an advanced two-metal binding pharmacophore.

  Journal of medicinal chemistry 20121025

• Antiviral drug advances in the treatment of human immunodeficiency virus (HIV) and chronic hepatitis C virus (HCV).

  Current opinion in pharmacology 20121001

• The future of integrase inhibitors of HIV-1.

  Current opinion in virology 20121001

• The development of novel HIV integrase inhibitors and the problem of drug resistance.

  Current opinion in virology 20121001

• Design, practical synthesis, and biological evaluation of novel 6-(pyrazolylmethyl)-4-quinoline-3-carboxylic acid derivatives as HIV-1 integrase inhibitors.

  Molecules (Basel, Switzerland) 20120906

• Drug resistance mutations of HIV type 1 non-B viruses to integrase inhibitors in treatment-naive patients from sub-saharan countries and discordant interpretations.

  AIDS research and human retroviruses 20120901

• Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function.

  Journal of acquired immune deficiency syndromes (1999) 20120901

• The use of HIV-1 integrase inhibitors in antiretroviral naive patients.

  Current opinion in HIV and AIDS 20120901

• Pharmacology of HIV integrase inhibitors.

  Current opinion in HIV and AIDS 20120901

• Combinational therapies for HIV: a focus on EVG/COBI/FTC/TDF.

  Expert opinion on pharmacotherapy 20120901

• HIV integrase inhibitors in ART-experienced patients.

  Current opinion in HIV and AIDS 20120901

• Tolerability of HIV integrase inhibitors.

  Current opinion in HIV and AIDS 20120901

• [A single tablet against HIV: new combination preparation improves therapy].

  Deutsche medizinische Wochenschrift (1946) 20120801

• In-vivo selection of the mutation F121Y in a patient failing raltegravir containing salvage regimen.

  Antiviral research 20120701

• The elvitegravir Quad pill: the first once-daily dual-target anti-HIV tablet.

  Expert opinion on investigational drugs 20120701

• Tenofovir: quo vadis anno 2012 (where is it going in the year 2012)?

  Medicinal research reviews 20120701

• Update on raltegravir and the development of new integrase strand transfer inhibitors.

  Southern medical journal 20120701

• Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial.

  Lancet (London, England) 20120630

• Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks.

  Lancet (London, England) 20120630

• Development of an AlphaScreen-based HIV-1 integrase dimerization assay for discovery of novel allosteric inhibitors.

  Journal of biomolecular screening 20120601

• A review of the virological efficacy of the 4 World Health Organization-recommended tenofovir-containing regimens for initial HIV therapy.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20120315

• Elvitegravir: a once-daily inhibitor of HIV-1 integrase.

  Expert opinion on investigational drugs 20120301

• Homology model-guided 3D-QSAR studies of HIV-1 integrase inhibitors.

  Journal of chemical information and modeling 20120227

• In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4.

  Antiviral research 20120201

• Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study.

  The Lancet. Infectious diseases 20120101

• Elvitegravir: a once daily alternative to raltegravir.

  The Lancet. Infectious diseases 20120101

• Elvitegravir: a once-daily, boosted, HIV-1 integrase inhibitor.

  Expert review of anti-infective therapy 20120101

• Diketoacid inhibitors of HIV-1 integrase: from L-708,906 to raltegravir and beyond.

  Current medicinal chemistry 20120101

• Review of the safety, efficacy, and pharmacokinetics of elvitegravir with an emphasis on resource-limited settings.

  HIV/AIDS (Auckland, N.Z.) 20120101

• The use of preexposure treatments for HIV prophylaxis.

  HIV/AIDS (Auckland, N.Z.) 20120101

• Genetic barrier to the development of resistance to integrase inhibitors in HIV-1 subtypes CRF01_AE and B.

  Intervirology 20120101

• Incomplete immune recovery in HIV infection: mechanisms, relevance for clinical care, and possible solutions.

  Clinical & developmental immunology 20120101

• BF integrase genes of HIV-1 circulating in São Paulo, Brazil, with a recurrent recombination region.

  PloS one 20120101

• Novel therapeutic strategies targeting HIV integrase.

  BMC medicine 20120101

• Antiretroviral drugs: critical issues and recent advances.

  Indian journal of pharmacology 20120101

• Development of elvitegravir resistance and linkage of integrase inhibitor mutations with protease and reverse transcriptase resistance mutations.

  PloS one 20120101

• In Silico and In Vitro Comparison of HIV-1 Subtypes B and CRF02_AG Integrases Susceptibility to Integrase Strand Transfer Inhibitors.

  Advances in virology 20120101

• Three main mutational pathways in HIV-2 lead to high-level raltegravir and elvitegravir resistance: implications for emerging HIV-2 treatment regimens.

  PloS one 20120101

• Investigating the role of metal chelation in HIV-1 integrase strand transfer inhibitors.

  Journal of medicinal chemistry 20111222

• The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype.

  The Journal of antimicrobial chemotherapy 20111201

• Recent advances in antiretroviral treatment and prevention in HIV-infected patients.

  Current opinion in HIV and AIDS 20111201

• HIV-1 integrase inhibitors: a review of their chemical development.

  Antiviral chemistry & chemotherapy 20111117

• 3-Hydroxy-6,7-dihydropyrimido[2,1-c][1,4]oxazin-4(9H)-ones as new HIV-1 integrase inhibitors WO2011046873 A1.

  Expert opinion on therapeutic patents 20111101

• Synthesis and biological evaluation of HQCAs with aryl or benzyl substituents on N-1 position as potential HIV-1 integrase inhibitors.

  Bioorganic & medicinal chemistry 20110915

• Structural modifications of quinolone-3-carboxylic acids with anti-HIV activity.

  Bioorganic & medicinal chemistry 20110815

• Microwave assisted organic synthesis (MAOS) of small molecules as potential HIV-1 integrase inhibitors.

  Molecules (Basel, Switzerland) 20110811

• New first and second generation inhibitors of human immunodeficiency virus-1 integrase.

  Expert opinion on therapeutic patents 20110801

• Resistance to raltegravir highlights integrase mutations at codon 148 in conferring cross-resistance to a second-generation HIV-1 integrase inhibitor.

  Antiviral research 20110801

• Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143.

  AIDS (London, England) 20110601

• Binding modes of diketo-acid inhibitors of HIV-1 integrase: a comparative molecular dynamics simulation study.

  Journal of molecular graphics & modelling 20110601

• HIV-1 integrase inhibitor resistance and its clinical implications.

  The Journal of infectious diseases 20110501

• Foamy virus biology and its application for vector development.

  Viruses 20110501

• Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir.

  Clinical pharmacokinetics 20110401

• Potential of novel antiretrovirals to modulate expression and function of drug transporters in vitro.

  The Journal of antimicrobial chemotherapy 20110401

• Clinical management of HIV drug resistance.

  Viruses 20110401

• Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection.

  AIDS (London, England) 20110327

• Allosteric inhibitor development targeting HIV-1 integrase.

  ChemMedChem 20110207

• In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.

  Antimicrobial agents and chemotherapy 20110201

• HIV-1 integrase strand-transfer inhibitors: design, synthesis and molecular modeling investigation.

  European journal of medicinal chemistry 20110201

• 6-Benzylamino 4-oxo-1,4-dihydro-1,8-naphthyridines and 4-oxo-1,4-dihydroquinolines as HIV integrase inhibitors.

  Bioorganic & medicinal chemistry letters 20110115

• Recent advances in antiretroviral drugs.

  Expert opinion on pharmacotherapy 20110101

• K70Q adds high-level tenofovir resistance to 'Q151M complex' HIV reverse transcriptase through the enhanced discrimination mechanism.

  PloS one 20110101

• Driving a decade of change: HIV/AIDS, patents and access to medicines for all.

  Journal of the International AIDS Society 20110101

• HIV integrase variability and genetic barrier in antiretroviral naïve and experienced patients.

  Virology journal 20110101

• Antiretroviral Therapy for HIV-2 Infection: Recommendations for Management in Low-Resource Settings.

  AIDS research and treatment 20110101

• Patterns of resistance development with integrase inhibitors in HIV.

  Infection and drug resistance 20110101

• HIV-2 integrase variation in integrase inhibitor-naïve adults in Senegal, West Africa.

  PloS one 20110101

• G140S/Q148R and N155H mutations render HIV-2 Integrase resistant to raltegravir whereas Y143C does not.

  Retrovirology 20110101

• A crystal structure of the catalytic core domain of an avian sarcoma and leukemia virus integrase suggests an alternate dimeric assembly.

  PloS one 20110101

• Pathogenicity and rapid growth kinetics of feline immunodeficiency virus are linked to 3' elements.

  PloS one 20110101

• In-silico Comparative Study and Quantitative Structure-activity Relationship Analysis of Some Structural and Physiochemical Descriptors of Elvitegravir Analogs.

  Journal of young pharmacists : JYP 20110101

• Role of raltegravir in the management of HIV-1 infection.

  HIV/AIDS (Auckland, N.Z.) 20110101

• Clinical Use of Inhibitors of HIV-1 Integration: Problems and Prospects.

  Acta naturae 20110101

• Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C.

  Viruses 20101201

• Modeling the HIV-1 Intasome: A Prototype View of the Target of Integrase Inhibitors.

  Viruses 20101201

• Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV.

  Journal of acquired immune deficiency syndromes (1999) 20101101

• Mutation Q95K enhances N155H-mediated integrase inhibitor resistance and improves viral replication capacity.

  The Journal of antimicrobial chemotherapy 20101101

• Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors.

  The Journal of antimicrobial chemotherapy 20101101

• Development of integrase inhibitors of quinolone acid derivatives for treatment of AIDS: an overview.

  Mini reviews in medicinal chemistry 20101001

• Physical trapping of HIV-1 synaptic complex by different structural classes of integrase strand transfer inhibitors.

  Biochemistry 20100928

• HIV-1 subtype B and C integrase enzymes exhibit differential patterns of resistance to integrase inhibitors in biochemical assays.

  AIDS (London, England) 20100910

• Novel antiretroviral combinations in treatment-experienced patients with HIV infection: rationale and results.

  Drugs 20100910

• Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor.

  Journal of virology 20100901

• Novel integrase inhibitors for HIV.

  Expert opinion on investigational drugs 20100901

• Bunyaviridae RNA polymerases (L-protein) have an N-terminal, influenza-like endonuclease domain, essential for viral cap-dependent transcription.

  PLoS pathogens 20100901

• Evolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy.

  Journal of acquired immune deficiency syndromes (1999) 20100801

• Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles.

  Virology 20100705

• Tautomerism and magnesium chelation of HIV-1 integrase inhibitors: a theoretical study.

  ChemMedChem 20100705

• Resistance to integrase inhibitors.

  Viruses 20100701

• HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens.

  The Journal of antimicrobial chemotherapy 20100601

• Biochemical and pharmacological analyses of HIV-1 integrase flexible loop mutants resistant to raltegravir.

  Biochemistry 20100504

• Retrovirus Integrase-DNA Structure Elucidates Concerted Integration Mechanisms.

  Viruses 20100501

• Natural polymorphisms of integrase among HIV type 1-infected South African patients.

  AIDS research and human retroviruses 20100401

• Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial.

  The Journal of infectious diseases 20100315

• Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity.

  Clinical pharmacology and therapeutics 20100301

• Single-tablet Quad regimen achieves high rate of virologic suppression.

  AIDS patient care and STDs 20100301

• Pharmacokinetic interaction of ritonavir-boosted elvitegravir and maraviroc.

  Journal of acquired immune deficiency syndromes (1999) 20100201

• Pharmacokinetics and drug-drug interactions of antiretrovirals: an update.

  Antiviral research 20100101

• Strand transfer inhibitors of HIV-1 integrase: bringing IN a new era of antiretroviral therapy.

  Antiviral research 20100101

• Integrase inhibitors: a novel class of antiretroviral agents.

  The Annals of pharmacotherapy 20100101

• Improving first-line antiretroviral therapy in resource-limited settings.

  Current opinion in HIV and AIDS 20100101

• Genetic diversity on the integrase region of the pol gene among HIV type 1-infected patients naive for integrase inhibitors in São Paulo City, Brazil.

  AIDS research and human retroviruses 20100101

• Response of a simian immunodeficiency virus (SIVmac251) to raltegravir: a basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapy.

  Retrovirology 20100101

• [Analysis of HIV-1 integrase gene polymorphism in an HIV-infected population from the nosocomial outbreak of HIV infection in the south of Russia in 1989].

  Voprosy virusologii 20100101

• The HIV-1 integrase mutations Y143C/R are an alternative pathway for resistance to Raltegravir and impact the enzyme functions.

  PloS one 20100101

• 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention: summary of key research and implications for policy and practice - clinical sciences.

  Journal of the International AIDS Society 20100101

• Anticipating and blocking HIV-1 escape by second generation antiviral shRNAs.

  Retrovirology 20100101

• Resistance to HIV-1 integrase inhibitors: A structural perspective.

  Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 20100101

• Susceptibility of the human retrovirus XMRV to antiretroviral inhibitors.

  Retrovirology 20100101

• Polymorphisms of HIV-2 integrase and selection of resistance to raltegravir.

  Retrovirology 20100101

• The HIV-1 integrase α4-helix involved in LTR-DNA recognition is also a highly antigenic peptide element.

  PloS one 20100101

• Extended use of raltegravir in the treatment of HIV-1 infection: optimizing therapy.

  Infection and drug resistance 20100101

• Role of etravirine in the management of treatment-experienced patients with human immunodeficiency virus type 1.

  HIV/AIDS (Auckland, N.Z.) 20100101

• A combined genotypic and phenotypic human immunodeficiency virus type 1 recombinant virus assay for the reverse transcriptase and integrase genes.

  Journal of virological methods 20091101

• Efavirenz: a decade of clinical experience in the treatment of HIV.

  The Journal of antimicrobial chemotherapy 20091101

• Integrase inhibitors in salvage therapy regimens for HIV-1 infection.

  Current opinion in HIV and AIDS 20091101

• Resistance to novel drug classes.

  Current opinion in HIV and AIDS 20091101

• Elvitegravir: a new HIV integrase inhibitor.

  Antiviral chemistry & chemotherapy 20091019

• In search of second-generation HIV integrase inhibitors: targeting integration beyond strand transfer.

  Future medicinal chemistry 20091001

• Induced-fit docking approach provides insight into the binding mode and mechanism of action of HIV-1 integrase inhibitors.

  ChemMedChem 20090901

• Quinolone carboxylic acids as a novel monoketo acid class of human immunodeficiency virus type 1 integrase inhibitors.

  Journal of medicinal chemistry 20090813

• Human immunodeficiency virus: 25 years of diagnostic and therapeutic strategies and their impact on hepatitis B and C virus.

  Medical microbiology and immunology 20090801

• Analysis of binding parameters of HIV-1 integrase inhibitors: correlates of drug inhibition and resistance.

  Bioorganic & medicinal chemistry 20090701

• Lack of primary mutations associated with integrase inhibitors among HIV-1 subtypes B, C, and F circulating in Brazil.

  Journal of acquired immune deficiency syndromes (1999) 20090501

• [New antiretroviral drug classes in HIV therapy].

  MMW Fortschritte der Medizin 20090430

• Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.

  Antimicrobial agents and chemotherapy 20090301

• Analysis of pol integrase sequences in diverse HIV type 1 strains using a prototype genotyping assay.

  AIDS research and human retroviruses 20090301

• Data demonstrate pharmacokinetic boosting activity of GS 9350.

  AIDS patient care and STDs 20090301

• Potent inhibitors of HIV-1 integrase display a two-step, slow-binding inhibition mechanism which is absent in a drug-resistant T66I/M154I mutant.

  Biochemistry 20090224

• New approaches for inhibiting HIV integrase: a journey beyond the active site.

  Current opinion in investigational drugs (London, England : 2000) 20090201

• Elvitegravir, an oral HIV integrase inhibitor, for the potential treatment of HIV infection.

  Current opinion in investigational drugs (London, England : 2000) 20090201

• Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure.

  Clinical pharmacology and therapeutics 20090101

• Emerging pharmacology: inhibitors of human immunodeficiency virus integration.

  Annual review of pharmacology and toxicology 20090101

• Novel targets for antiretroviral therapy: clinical progress to date.

  Drugs 20090101

• Raltegravir, elvitegravir, and metoogravir: the birth of 'me-too' HIV-1 integrase inhibitors.

  Retrovirology 20090101

• Characterization and structural analysis of HIV-1 integrase conservation.

  AIDS reviews 20090101

• Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02_AG subtypes.

  Antiviral therapy 20090101

• Novel compounds for the treatment of HIV type-1 infection.

  Antiviral chemistry & chemotherapy 20090101

• Drug interactions with new and investigational antiretrovirals.

  Clinical pharmacokinetics 20090101

• Emerging role of integrase inhibitors in the management of treatment-experienced patients with HIV infection.

  Therapeutics and clinical risk management 20090101

• Pharmacotherapy of pediatric and adolescent HIV infection.

  Therapeutics and clinical risk management 20090101

• Comparative biochemical analysis of HIV-1 subtype B and C integrase enzymes.

  Retrovirology 20090101

• Raltegravir: The evidence of its therapeutic value in HIV-1 infection.

  Core evidence 20090101

• Pharmacologic and nonpharmacologic options for the management of HIV infection during pregnancy.

  HIV/AIDS (Auckland, N.Z.) 20090101

• Design, synthesis, and biological evaluation of a series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones as dual inhibitors of human immunodeficiency virus type 1 integrase and the reverse transcriptase RNase H domain.

  Journal of medicinal chemistry 20081225

• Selection of diverse and clinically relevant integrase inhibitor-resistant human immunodeficiency virus type 1 mutants.

  Antiviral research 20081101

• HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro.

  The Journal of antimicrobial chemotherapy 20081101

• [Resistance to integrase inhibitors].

  Enfermedades infecciosas y microbiologia clinica 20081101

• Effect of ritonavir-boosted tipranavir or darunavir on the steady-state pharmacokinetics of elvitegravir.

  Journal of acquired immune deficiency syndromes (1999) 20081001

• Clade-specific HIV-1 integrase polymorphisms do not reduce raltegravir and elvitegravir phenotypic susceptibility.

  AIDS (London, England) 20080912

• Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants.

  Biochemistry 20080909

• Emerging antiviral drugs.

  Expert opinion on emerging drugs 20080901

• Phase III trial begins for elvitegravir.

  AIDS patient care and STDs 20080901

• Investigations on the 4-quinolone-3-carboxylic acid motif. 1. Synthesis and structure-activity relationship of a class of human immunodeficiency virus type 1 integrase inhibitors.

  Journal of medicinal chemistry 20080828

• Preclinical evaluation of 1H-benzylindole derivatives as novel human immunodeficiency virus integrase strand transfer inhibitors.

  Antimicrobial agents and chemotherapy 20080801

• Genetic diversity of integrase (IN) sequences in antiretroviral treatment-naive and treatment-experienced HIV type 2 patients.

  AIDS research and human retroviruses 20080701

• Integrase inhibitors: a clinical review of raltegravir and elvitegravir.

  Journal of HIV therapy 20080601

• A refined pharmacophore model for HIV-1 integrase inhibitors: Optimization of potency in the 1H-benzylindole series.

  Bioorganic & medicinal chemistry letters 20080501

• Pharmacologic characteristics of investigational and recently approved agents for the treatment of HIV.

  Current opinion in HIV and AIDS 20080501

• Raltegravir: first in class HIV integrase inhibitor.

  Therapeutics and clinical risk management 20080401

• Quinolone 3-carboxylic acid pharmacophore: design of second generation HIV-1 integrase inhibitors.

  Journal of medicinal chemistry 20080313

• Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137).

  Journal of virology 20080101

• Integrase inhibitors: a new treatment option for patients with human immunodeficiency virus infection.

  Pharmacotherapy 20080101

• HIV-1 drug resistance mutations: an updated framework for the second decade of HAART.

  AIDS reviews 20080101

• Emerging therapies for hepatitis C and HIV in drug abusers: drugs and strategies.

  Journal of addictive diseases 20080101

• Natural variation of HIV-1 group M integrase: implications for a new class of antiretroviral inhibitors.

  Retrovirology 20080101

• Antiviral Chemistry & Chemotherapy's current antiviral agents FactFile (2nd edition): retroviruses and hepadnaviruses.

  Antiviral chemistry & chemotherapy 20080101

• Comparing two integrase inhibitors. The first head-to-head study comparing raltegravir and elvitegravir.

  Positively aware : the monthly journal of the Test Positive Aware Network 20080101

• Integrase and integration: biochemical activities of HIV-1 integrase.

  Retrovirology 20080101

• Pharmacokinetics of elvitegravir and etravirine following coadministration of ritonavir-boosted elvitegravir and etravirine.

  Antiviral therapy 20080101

• Raltegravir in the management of HIV-infected patients.

  Drug design, development and therapy 20080101

• Substituted 2-pyrrolinone inhibitors of HIV-1 integrase.

  Bioorganic & medicinal chemistry letters 20071115

• Mirabamides A-D, depsipeptides from the sponge Siliquariaspongia mirabilis that inhibit HIV-1 fusion.

  Journal of natural products 20071101

• Antiviral drugs in the treatment of AIDS: what is in the pipeline ?

  European journal of medical research 20071015

• Pharmacokinetics of coadministered ritonavir-boosted elvitegravir and zidovudine, didanosine, stavudine, or abacavir.

  Journal of acquired immune deficiency syndromes (1999) 20071001

• Pharmacokinetics of emtricitabine, tenofovir, and GS-9137 following coadministration of emtricitabine/tenofovir disoproxil fumarate and ritonavir-boosted GS-9137.

  Journal of acquired immune deficiency syndromes (1999) 20070701

• In-Silico docking of HIV-1 integrase inhibitors reveals a novel drug type acting on an enzyme/DNA reaction intermediate.

  Retrovirology 20070101

• Human immunodeficiency virus integrase inhibitors efficiently suppress feline immunodeficiency virus replication in vitro and provide a rationale to redesign antiretroviral treatment for feline AIDS.

  Retrovirology 20070101

• Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients.

  Journal of acquired immune deficiency syndromes (1999) 20060901

• Novel HIV-1 integrase inhibitors derived from quinolone antibiotics.

  Journal of medicinal chemistry 20060309

• MK-0518 and GS-9137: two promising integrase inhibitors in the pipeline.

  BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation 20060101

• Integrase inhibitors to treat HIV/AIDS.

  Nature reviews. Drug discovery 20050301

• Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells.

  Science (New York, N.Y.) 20000128